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bstract
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment
f advanced NSCLC patients. These drugs target one of the most important pathways in lung carcinogenesis and are able to exploit the
henomenon of ‘oncogene addiction’, with different efficacy according to EGFR gene mutational status in tumor samples. Gefitinib has
een approved only for EGFR mutation bearing patients regardless the line of treatment, while erlotinib is also indicated in patients without
GFR mutation who undergo second- or third-line treatment. Some studies evaluated the main differences between these drugs both for
irect comparison and to improve their sequential use. In particular, toxicity profile resulted partially different, and these observations may
e explained by several molecular and pharmacokinetic features. Therefore, this review integrates preclinical data with clinical evidences of
KIs to guide the optimization of currently available treatments in advanced NSCLC patients.
 2013 Published by Elsevier Ireland Ltd.
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.  Introduction
.1.  Deﬁnition  of  EGFR-TKIs  drugs
The management of NSCLC patients can today take
dvantage from the use of innovative targeted agents, such
s erlotinib and gefitinib. The rationale for the efficacy of
hese small tyrosine kinase inhibitor (TKI) molecules lies in
he so called “oncogene addiction” hypothesis, according to
hich some mutations that occur in specific oncogenes may
ender cancer cell survival strictly dependent on that aber-
ant gene [1,2]. Thus, drugs that are able to inactivate the
utated gene offer a new important strategy in the treatment
f selected subgroups of tumors.
Gefitinib and erlotinib are orally active EGFR TKIs with
ifferent structure, as also reflected by the different molec-
lar weight (446.9 Da and 429.9 Da, respectively). These
rugs are ATP competitors at the ATP-binding pocket in
he intracellular domain of EGFR [3]. As a consequence
f this inhibition, cellular proliferation, angiogenesis, tumor
nvasion, and metastatic potential are inhibited. Gefitinib
s available as film-coated tablets that contain 250 mg of
ctive compound. Erlotinib tablets are available in three dose
trengths: 25 mg, 100 mg, and 150 mg.
.2.  EGFR  Pathway
Epidermal growth factor receptor (EGFR) is a trans-
embrane protein with cytoplasmic kinase activity that
ransduces growth signaling from the extracellular environ-
ent to the cell. The EGFR gene is located on the short arm of
hromosome 7 (7p11.2) and encodes a 170 kDa type I trans-
embrane growth factor receptor [4]. EGFR belongs to the
ER/erbB family receptor tyrosine kinases, which includes
ER1 (EGFR/erbB1), HER2 (neu, erbB2), HER3 (erbB3)
nd HER 4 (erbB4). The interaction of EGFR extracellular
omain with specific ligands induces a homo-dimerization
or hetero-dimerization with other HER family members)
hat causes the activation of the TK domain resulting in
yrosine autophosphorylation. Multiple signaling pathways
re then activated, including RAS/RAF/ERK/MAPK and
I3K/AKT pathways [5]. These pathways regulate several
a
a
m
cntracellular processes such as proliferation, invasion, cellular
epair, protection from injury and anti-apoptosis [6].
. Biological  bases  of  EGFR-TKIs  treatment
.1.  EGFR  mutational  status  and  resistance  mutations
Until April 2004 it was unclear how to identify NSCLC
atients who would benefit from the use of erlotinib or
efinitib. The data from the retrospective analysis of BR.21
rial about erlotinib in pretreated patients suggest that never-
mokers and patients with EGFR-positive tumors might
xperience an enhanced benefit from erlotinib compared to
lacebo [7]. Higher response rates were also associated with
atient characteristics such as never-smoking status, female
ender, adenocarcinoma histotype, and East Asian race. Nev-
rtheless it was clear from the outset that not all patients
esponded in the same way to the treatment with these drugs.
hen, two research groups from Boston revealed that EGFR
ene mutations in the kinase domain are strongly associated
ith TKIs sensitivity [8–10].
The sensitizing mutations to TKIs treatment fall within
GFR kinase domain and are activating mutations. To
ate four main types of EGFR activating mutations have
een identified: point mutation in exon18 (G719X, G719S,
719A), deletions in exon19, insertions in exon20, and
oint mutation in exon21 (L858R and L861Q). The most
requent mutations are exon19 deletions (over 20 variant
ypes) and leucine-to-arginine mutation at codon 858 in
xon21 (L858R), accounting for 90% of all EGFR mutations.
everal cell-based studies demonstrated that these muta-
ions increased autophosphorylating activity on intracellular
yrosines determining the activation of a subset of down-
tream effectors. In addition, the mutant kinases are more
ensitive to inhibition by gefitinib and erlotinib, which seems
o reflect their increased drug affinity [11].
Despite the efficacy of EGFR-targeted therapy in NSCLC,
lmost all patients develop resistance to these drugs, with
 mean duration of the response ranging between 3 and 7
onths [12,13]. Beyond all the activating mutations that
onfer sensitivity to TKIs, there are indeed other point
3  Oncology/Hematology 89 (2014) 300–313
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Fig. 1. EGFR activating mutation. The main mutation types identified in
EGFR gene are: point mutation in exon18 (G719X, G719S, G719A), dele-
tions in exon19, insertions in exon20, and point mutation in exon21 (L858R
and L861Q). Point mutation in exon18 and insertions in exon20 account for
4% of all EGFR mutations; the most frequent mutations are exon19 dele-
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utations that may determine resistance to TKIs treatment.
he most common resistance mutation is the T790M (substi-
ution of threonine to methionine on codon 790), which falls
nto exon20. This mutation cause the insertion of a bulky
ethionine over the ATP binding pocket, blocking access to
GFR-TKIs but not to ATP [14]. Because of its significant
ole in affecting TKIs activity, the T790M should also be eval-
ated before the beginning of the treatment. This mutation
as been thought to cause resistance by sterically blocking
inding of TKIs such as gefitinib and erlotinib, but this expla-
ation is in contrast with the fact that it remains sensitive to
tructurally similar irreversible inhibitors. Subsequent stud-
es showed that T790M mutation increased the affinity of
he receptor for ATP [15] and that T790M mutants retain
ow-nanomolar affinity for TKIs, in particular gefitinib [14].
his mutation occurs in cis of the same allele as the origi-
al activating mutations (it may be either an exon19 deletion
r an exon21 L858R mutation). Interestingly, data from a
ecent study have unraveled the predictive value of T790M
16]. This study analyzed 95 patients enrolled in EURTAC
rial for T790M end P53 mutations, EML4-ALK transloca-
ion and BIM mRNA expression levels. The results showed
hat OS for patients with T790M mutations was 40.1 months
n those with high BIM levels and 15.4 months in patients
ith low/intermediate BIM levels (P  = 0.04). These findings
hould lead to the design of studies of treatment based on
he presence of the EGFR T790M mutation and BIM expres-
ion levels. In addition to the EGFR T790M mutation, there
re other uncommon secondary resistance mutations, such as
854A in exon21 [17], as well as L747S [18], and D761Y
19], both in the exon19. T854A mutation has a compara-
le effect to that of T790M; L747S is thought to shift the
quilibrium toward the active conformation of the receptor,
hile D761Y may affect the catalytic cleft of the receptor
20] (Figs. 1–4).
.2.  EGFR-TKIs  mechanisms  of  action
Both gefitinib and erlotinib exert their action by interac-
ing with EGFR ATP binding pocket and thereby blocking the
ignal transduction. EGFR mutations make the cancer cells
ore sensitive to these drugs through the phenomenon of
oncogene addiction”, which provides a rationale for molec-
lar targeted therapy. The blockade of this pathway leads to
umor cell death, while sparing EGFR wild type cells. Despite
any studies support the concept of this phenomenon, the
nderlying biological and molecular mechanisms are not
et clear. Zhou and collaborators have recently developed a
athemathic model of EGFR-associated signaling network
o investigate possible molecular mechanisms of tumor cell
eath [21].
EGFR activation results in the initiation of different
ellular pathways. In response to several stimuli (toxic envi-
onmental stimuli or receptor occupation by the ligands EGF,
ransforming growth factor-  and neuregulins), the EGFR
orms homo- or heterodimers with other family members and
k
b
c
fions (over 20 variant types) and leucine-to-arginine mutation at codon 858
n exon21 (L858R), accounting for 90% of all EGFR mutations.
ll the possible complexes between ErbB family members
ave been already identified [22]. The three heterodimers
hat are most frequently formed are ErbB-2/ErbB-3, ErbB-
/ErbB-4, and ErbB1/ErbB-4 and the different ability to form
omo- and heterodimers is dictated by receptors expression
evels. Receptor dimerization is followed by activation of
ntrinsic protein tyrosine kinase activity and tyrosine phos-
horylation. These lead to the formation of phospho-tyrosine
esidues that enable receptor to recruit adaptor proteins such
s Shc and Grb2 [23]. Several studies have also shown that
he phosphorylation of specific tyrosine residues is able to
ecruit specific cytosolic proteins, and then activate different
athways [11]. For example Purvis and collaborators [24]
ssumed that phosphorylated Y1068 (pY1068) binds mainly
o Gab-1 and Grb2 while phosphorylated Y1173 (pY1173)
inds preferentially to Shc. This introduces the concept that
ifferential signaling is headed by the phosphorilation of
ifferent tyrosine residues that transduce signal through dis-
inctive/diverse pathways. Once bound to the receptor Shc
nd Grb2 recruit SOS that promotes the replacement of GDP
y GTP in Ras, thereby activating Ras. This activation in
urns lead to the phosphorylation of Raf and hence the MAPK
athway is activated. Conversely, the interaction of the EGFR
ith Gab-1 leads to the recruitment of phosphatidylinositol 3-
inase (PI3K), which induces the activation of AKT pathway
y transforming PIP2 in PIP3 [25–29]. An internal pro-
ess of negative feedback regulates both these pathways. In
act, activated ERK can also phosphorylate the protein SOS
G. Bronte et al. / Critical Reviews in Oncology/Hematology 89 (2014) 300–313 303
Fig. 2. EGFR pathway: Receptor dimerization lead to the activation of intrinsic protein tyrosine kinase activity and tyrosine phosphorylation. The phosphor-
ylation of different tyrosine residues enables the receptor to recruit adaptor protein such as Shc and Grb2. Phosphorylated Y1068 (pY1068) binds mainly to
G  to Shc. The recruitment of SOS promotes the replacement of GDP by GTP in Ras,
t  of Raf and hence the MAPK pathway is activated. Instead the interaction of the
E (PI3K), that by transforming PIP2 in PIP3 induces the activation of AKT pathway.
i
P
P
t
a
t
t
R
t
A
a
p
c
b
b
b
s
a
2
b
e
o
s
t
Fig. 3. TKIs supposed mechanism of action. Orally administered gefitinib
(or erlotinib) is taken up by cancer cells, and it reversibly and competitivelyab-1 and Grb2 while phosphorylated Y1173 (pY1173) binds preferentially
hereby activating Ras. This activation in turns lead to the phosphorylation
GFR with Gab-1 leads to the recruitment of phosphatidylinositol 3-kinase 
nducing the dissociation of Grb2-SOS from the receptor.
IP3 and Akt are instead dephosphorylated by PTEN and
P2A, respectively. P38 is an important pro-apoptotic effec-
or that can be activated by a variety of environmental stresses,
mong them the most important is the stress due to reac-
ive oxygen species (ROS). Numerous studies have shown
hat stimulation of neoplastic cells with EGF can induce
OS production thus activating P38 [30]. The acute inac-
ivation of EGFR results in a drastic decline of p-ERK and
KT and a delayed increase of P38. This finally results in
 rapid decrease of proliferative stimuli and an increase of
ro-apoptotic signals in addicted cancer cells [31].
Orally administered gefitinib or erlotinib are taken up by
ancer cells, and they reversibly and competitively inhibit the
inding of ATP to the phosphate-binding loop. By the inhi-
ition of ATP binding to EGFR, the EGFR-TKIs therefore
lock auto-phosphorylation and the activation of downstream
ignaling pathways, leading to the inhibition of cell prolifer-
tion and the induction of apoptosis in cancer cells [32].
.3.  Biological  hypotheses  to  explain  the  differences
etween  erlotinib  and  geﬁtinib
The analysis of clinical data suggests a difference in the
ffectiveness of erlotinib and gefitinib. We present hypotheses
n the biological basis of this difference to improve the under-
tanding of TKIs’ biological function. We hypothesize that
he different response to gefitinib and erlotinib may depend on
inhibits the binding of ATP to the phosphate-binding loop. By the inhibition
of ATP binding to EGFR, EGFR-TKIs therefore block auto-phosphorylation
and the activation of downstream signaling pathways, leading to the inhibi-
tion of cell proliferation and the induction of apoptosis in cancer cells.
304 G. Bronte et al. / Critical Reviews in Oncolo
Fig. 4. Erlotinib and gefitinib chemical structures. Erlotinib and gefiti-
nib (molecular mass 429.9 and 446.9 respectively) are both based on a
4-anilino-quinazoline kinase pharmacophore and exhibit similar pharma-
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After oral assumption erlotinib is slowly absorbed andokinetic characteristics in patients after oral administration, with extensive
etabolism primarily by cytochrome P450 3A4 in liver.
he effects of various EGFR mutations on receptor structure,
rimarily on catalytic site. This hypothesis is supported by
un and collaborators, stating that the effect of the mutations
n inhibitor binding site is important, because they cluster
round the catalytic cleft and differences in inhibitor sen-
itivity of the mutants have been reported [15]. This study
uggests that mutations L858R and G719S have a different
ffect on the sensitivity to gefitinib, showing that L858R binds
ore tightly to gefitinib compared to G719S mutant. This
arkedly tighter binding of gefitinib to L858R mutant could
xplain its effectiveness against cells bearing this mutation.
n particular L858R transformed Ba/F3 cells are significantly
ore gefitinib-sensitive than G719S transformed cells [32].
hese data show that intrinsic differences in the inhibitor
inding affinity of the altered EGFR kinases might explain
he differential sensitivity of cell lines and tumor cells bearing
858R and G719S proteins.
Moreover, the combination of two different mutations
ould confer resistance to a TKI but improve sensitivity to the
ther one. In particular, an EGFR mutation E884K, in combi-
ation with L858R, was identified in a patient with advanced
ung cancer who progressed on erlotinib maintenance ther-
py, and subsequently had leptomeningeal metastases that
esponded to gefitinib [33].
Several other EGFR mutations might also play a rele-
ant role in this context and further studies are necessary
r
a
mgy/Hematology 89 (2014) 300–313
o investigate this possibility. More than 75 different EGFR
inase domain residues have been reported to be altered in
SCLCs. Using transfection of an YFP-tagged fragment of
he EGFR intracellular domain (YFP-EGFR-ICD), followed
y immunofluorescence microscopy analysis, recent stud-
es demonstrated that the exon 20 insertions Ins770SVD,
ns774HV N771GY and A767-V769 confer increased kinase
ctivity, but no sensitivity to erlotinib at clinically available
oncentrations [34]. However, a more recent study showed
hat sensitivity to erlotinib and gefitinib differed among sev-
ral EGFR mutations at exon 19 [35]. Moreover, gefitinib and
rlotinib seems to have slightly different activity also for the
ild-type EGFR receptor, since esponse rates of gefitinib in
SCLC with wild-type EGFR range from 0 to 6.6% in several
hase III trials [36–39], while the response rate of erlotinib
n NSCLC with wild-type EGFR was 7% in the BR.21 study
40]. Although one should be cautious in interpreting these
esults since the detection method of EGFR mutations var-
ed from study to study, further studies with standardized
ethods may help the clinician in patient management and
ay also improve the research of new and more potent TKIs
elective for specific mutations.
Finally, several research groups are investigating the possi-
le role of EGFR polymorphisms in the response and toxicity
o TKIs treatment [41]. Germline polymorphisms can be eas-
ly assessed in blood samples, and candidate polymorphisms
n EGFR have been correlated with outcome in NSCLC
atients treated with gefitinib or erlotinib [42]. In particu-
ar, EGFR -191C/A, -216 G/T, and R497K polymorphisms
ave been associated with gastrointestinal toxicity both in
efitinib and erlotinib-treated patients, while AKT1-SNP4
/A genotype seems to be a candidate biomarker of primary
esistance, when using gefitinib in NSCLC patients [43], but
ot in the pharmacogenetic analysis of the BR.21 random-
zed phase III clinical trial of erlotinib [44]. Despite these
ntriguing findings, the small sample size, together with the
nterethnic differences, and the retrospective nature of most
harmacogenetic studies, make it difficult to draw any clear
onclusions regarding the role of these biomarkers in deter-
ining the differential clinical outcome or toxicity in gefitinib
nd erlotinib treatment. Hopefully, the accurate planning of
ew prospective trials, the increased knowledge of key mech-
nisms affecting drug distribution/activity, and the use of
ovel technologies, including genome-wide approaches, may
rovide critical and essential tools to improve our insights in
GFR-TKIs mechanisms of action, in order to optimize these
reatments in selected NSCLC patients.
.  Pharmacokinetics
.1.  Bioavailabilityeaches its maximum plasma concentration after 3–4 h with
 mean bioavailability of 60%. One study provided an esti-
ate of the absolute bioavailability of 59%. At a dose of
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50 mg daily erlotinib keep an area under curve (AUC) of
8.420 ng.h/ml [45]. This value is about seven-fold higher
han those which could be obtained by administering thera-
eutic doses of gefitinib. Thus, the standard dose of erlotinib
ields a higher exposure, and a patient should receive >3-
old recommended dose of gefitinib, which is 250 mg, to
btain drug concentrations equivalent to those achievable by
rlotinib.
The solubility of both erlotinib and gefitinib is pH-
ependent. Agents that alter gastric pH, such as H2-receptor
ntagonists and proton-pump inhibitors can substantially
educe the plasma levels of EGFR TKIs, and their concomi-
ant use should be avoided. Moreover, both the bioavailability
nd the AUC of erlotinib increase considerably when the drug
s ingested with food [46]. Erlotinib has an oral bioavailabil-
ty of 60% when taken on an empty stomach. Conversely,
hen taken with food, erlotinib has a bioavailability of nearly
00%, which potentiates side effects. Therefore, erlotinib
hould be taken at least 1 h before or 2 h after a meal. After
–8 days erlotinib concentrations reach steady-state and its
limination half-life is 31 h. Erlotinib is evenly distributed
n the plasma and tumor tissue (plasma: tumor ratio = 1:1).
inding to plasma proteins is approximately 95% bound to
erum albumin and alpha-1 acid glycoprotein (AAG) of the
erum. For erlotinib a 30% dose reduction is allowed. This
ose reduction regards 6–16% of patients because of side
ffects.
In contrast, food does not affect the absorption of gefitinib.
he absorption after oral administration is moderately slow
nd peak plasma concentrations are obtained after 3–7 h from
dministration, with elimination half-life of 48 h, and mean
ioavailability of 60%. This drug is distributed extensively
n tissues, and plasma protein binding is approximately 90%
47].
.2.  Metabolism  and  clearance
Erlotinib and gefitinib are metabolized primarily by
YP3A4 and less by CYP3A5 and CYP1A1 [48]. Erlotinib
s metabolized primarily in the liver by different cytochrome
nzymes (especially by CYP3A4), but intestinal and lung
ancer cells could partly contribute to its catabolism. More-
ver, cigarette smoking induces CYP1A1 and has been
orrelated with a reduction in erlotinib exposure after a ther-
peutic dose [49].
Erlotinib excretion is >90% by stools and the rest by kid-
ey. Less than 2% of delivered dose is excreted as unchanged
rug. Also gefitinib is excreted mainly as metabolites in
tools, with renal elimination accounting for <4% of the
dministered dose.
However, erlotinib lipophilicity is about 3-times lower
han gefitinib. This could help to explain some of the differ-
nces in pharmacokinetic and pharmacodynamic properties
f the two compounds, since a greater lipophilicity also leads
o a higher susceptibility to the action of catabolic mech-
nisms, an increase in biliary excretion and a decrease in
s
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lasma concentrations of free drug. In fact erlotinib is less
xposed to hepatic cytochrome enzyme action, resulting in a
lower clearance.
The factors related to the patient that showed a correla-
ion with the pharmacokinetics of erlotinib were serum total
ilirubin, Alpha-1 Acid Glycoprotein (AAG) and current
moking. Increased serum concentrations of total bilirubin
nd AAG concentrations were associated with a reduced
rlotinib clearance. An interesting data on the pharmacoki-
etics of erlotinib is given by its interaction with smoke, so
hat smoker’s drug exposure is reduced by 50–60% and the
aximum tolerated dose is increased to 300 mg [49]. For
his reason smoking cessation should be suggested before
reatment starts.
. Clinical  aspects
EGFR-TKIs represent the mainstream target therapy in
SCLC lung cancer, leading to improvements in PFS and OS
hen used as upfront treatment in patients whom tumors har-
or EGFR mutations [50]. Instead of chemotherapy, which
nduces limited benefit on a large proportion of NSCLC
atients, targeted drugs are able to obtain a higher benefit
n a limited number of selected patients, with a lower tox-
city and a better quality of life. Therefore targeted drugs
mprove the concept of tailored therapy, which will lead to
ew algorithms taking into account clinical characteristics,
istology, molecular profiling such as genomics, and indi-
idual genes pattern. It represents the new frontier of cancer
reatment without using chemotherapeutic drugs, even if, at
his time, these progresses have had only a limited impact
n the overall outcome, and chemotherapy remains the only
ossible treatment for the most part of NSCLC patients [51].
The first clinical trials evaluating the TKIs efficacy in the
reatment of NSCLC patients date back to 2003–2005. On
he basis of encouraging pre-clinical results, some phase III
tudies were designed to evaluate the efficacy of gefitinib and
rlotinib in combination with the chemotherapeutic second-
ine treatment [12,52] and the first-line [53–55]. However
hese results were clearly negative. More recently, a further
hase III study [56], evaluated the addition of erlotinib to first-
ine cisplatin-gemcitabine chemotherapy in stage IIIB–IV
SCLC patients. The authors concluded that erlotinib with
oncurrent cisplatin-gemcitabine shows no benefit compared
o chemotherapy-naive NSCLC patients.
.1.  Comparison  of  clinical  trials  results  (ﬁrst  line,
econd line  and  maintenance)
.1.1.  Use  in  pretreated  patients
On the basis of encouraging results emerging from phase IItudies, which showed a good activity profile of gefitinib and
rlotinib as second/third line treatment in terms of response
ate (RR), two randomized phase III trials comparing the
fficacy of both drugs versus placebo were conducted [57,58].
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Table 1
Randomized phase III trials of comparison of TKI vs. placebo in pre-treated
patients with advanced NSCLC.
Clinical trials BR.21 [36] ISEL [37]
Treatment Erlotinib vs. placebo Gefitinib vs.
placebo
Median OS 6.7 vs. 4.7 months 5.6 vs. 5.1 months (HR:
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standard chemotherapy in terms of PFS (5.7 vs. 5.8 months),
T
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M(HR: 0.73; p: 0.001) 0.89; p: 0.1)
n particular BR21 study, which enrolled 731 patients with
SCLC in second/third line treatment, achieved the primary
ndpoint, overall survival (OS), with an extension of 42%
f the median survival in the erlotinib group compared with
lacebo (OS: 6.7 vs. 4.7 months, HR: 0.73, p: 0.001).
A multivariate subsequent analysis of the study showed a
reater RR in the erlotinib arm in a subgroup of patients
elected on the basis of certain clinical characteristics
women, non-smokers, Asian race, adenocarcinoma). These
haracteristics are associated with a higher probability of
GFR gene mutation, but BR21 data showed a statistically
ignificant benefit even in the subgroup of male patients,
mokers, squamous histology, leading to the drug registration
ith indication for treatment of 2–3 line in NSCLC patients
ot selected on the basis of clinical or biomolecular features.
With regard to gefitinib, the phase III trial which compared
efitinib vs. placebo in the treatment of 2nd–3rd line NSCLC
atients, ISEL [58], didn’t reached the primary endpoint (OS:
.6 months in the gefitinib arm vs. 5.1 in the placebo arm, HR:
.89, p: 0.1), although subgroup of analysis showed a statis-
ically significant advantage in favor of gefitinib in patients
ith certain clinical characteristics (i.e. women, Asian, not
mokers, adenocarcinoma), as described above. Indeed the
ate of responses obtained with gefitinib in the ISEL study
8%) is very similar to the one obtained with erlotinib in
R21 (9%), and the progression-free survival (PFS) as well
s the OS data seem overlapping.
The different final results achieved in these two studies
ould be attributed to the different chemosensitivity of the
wo selected populations. In fact, one of the inclusion criteria
f the ISEL trial was that patients had a progressive disease
ithin 90 days from the last cycle of performed chemother-
py, so that about 45% of patients in the ISEL study had a
D as the best response to treatment compared to 18% of the
atients in BR21 study (Table 1).Four following clinical trials compared gefitinib versus
ocetaxel in second line treatment. The INTEREST study
59], designed as a noninferiority trial, enrolled 1466 patients
w
1
o
able 2
andomized phase III trials of comparison of TKI vs chemotherapy in pre-treated p
linical trials INTEREST [38] SIGN [39] ISTANA [40]
reatment Gefitinib vs.
docetaxel
Gefitinib vs.
docetaxel
Gefitinib vs.
docetaxel
edian OS 7.6 vs. 8 months
(HR: 1.02)
7.5 vs. 7.1 months 14.1 vs. 12.2
months (HR: gy/Hematology 89 (2014) 300–313
fter 1–2 chemotherapy regimens not selected on the basis
f clinical or molecular characteristics, reaching their objec-
ive in full (HR: 1.02 96% CI: 0.905–1.15), with a median
urvival of 7.6 months for gefitinib vs. 8 months for CT.
lso the study SIGN [60] showed similar results in terms of
S (7.5 months vs. 7.1 months for gefitinib and docetaxel
espectively), as well as the two Asian studies ISTANA [61]
nd V15-32 [38], in which the higher median survival (14.1
onths), can be regarded as the general treatment outcomes
n unselected East Asian patients, while the results of INTER-
ST may represent general treatment outcomes in Western
ountries. A recent meta-analysis [62] summarizes and rein-
orces the results that emerge from individual studies, not
howing a statistically significant difference in OS and PFS
etween treatment with gefitinib and docetaxel in the 2nd–3rd
ine; but a higher RR%, a better toxicity profile and a better
uality of life were associated with gefitinib treatment, so that
he authors conclude that it would be preferable to docetaxel.
Next, three randomized phase III trials compared erlotinib
nd chemotherapy in the treatment of 2nd–3rd line NSCLC
atients not selected on the basis of clinical or biomolecu-
ar characteristic. In the TITAN trial [63], which compared
rlotinib vs. docetaxel or pemetrexed, OS (primary endpoint)
as similar in the two treatment arms (5.3 months in erlotinib
rm vs. 5.5 months in the CT arm, HR: 0.95, p: 0.73). In a
imilar study [64], in patients treated with erlotinib vs. peme-
rexed, time to progression (TTP) seems not different between
he two treatment arms, while primary endpoint data (OS) of
AILOR study, comparing erlotinib vs. docetaxel, are not yet
vailable, although some partial results of the study, concern-
ng the secondary endpoint (PFS) presented at ASCO 2012,
eem to highlight a benefit in favor of docetaxel (HR: 0.69,
5% CI: 0.52–0.93) (Table 2).
.1.2. Use  for  ﬁrst-line  treatment
The strong evidences concerning EGFR gene activating
utations and their correlation with the efficacy of TKI,
rompted several clinical trials to evaluate the use of these
rugs in the first-line treatment of NSCLC patients in Asia.
he Phase III study IPASS [39] compared gefitinib vs.
arboplatin–paclitaxel in a population of patients selected
n the basis of clinical features (Asian, non-smoking, ade-
ocarcinoma), demonstrating non-inferiority of gefitinib vs.hich was the primary endpoint, as well as for OS (18.6 vs.
7.3 months), with a tolerability profile and a better quality-
f-life in patients treated with gefitinib.
atients with advanced NSCLC.
 V15-32 [41] TITAN [43] TAILOR
Gefitinib vs.
docetaxel
Erlotinib vs.
doc/pem
Erlotinib vs.
docetaxel
0.87)
11.5 vs. 14
months (HR: 1.12)
5.3 vs. 5.5 months
(HR: 0.95)
Not yet available
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Subsequently the analysis of subgroups selected on
he basis of molecular factors [65] showed a statistically
ignificant advantage in favor of gefitinib in the subgroup
f patients harboring EGFR gene activating mutations, both
n terms of PFS (HR: 0.48, p  < 0.0001) and RR (43% vs. 32%,
 < 0.001), whereas no difference was observed regarding
S. Similar results were reported in a randomized phase III
orean study, FIRST SIGNAL [66], which compared gefiti-
ib vs. cisplatin–gemcitabine combination, not showing any
ifference between the two treatment arms (PFS 6.1 vs. 6.6
onths) in the general population selected on the basis of
linical features, while a statistically significant difference
n favor of gefitinib was observed in the subgroup of EGFR
utated patients (PFS 8.7 vs. 6.7 months).
In 2010 two randomized Japanese trials, NEJ002
nd WJTOG [67,68], compared in first-line treatment of
SCLC gefitinib vs. carboplatin–paclitaxel and gefitinib vs.
isplatin–docetaxel, respectively. Patients were selected for
he presence of EGFR gene activating mutations, and the
esults showed the clear superiority of gefitinib in this sub-
et of patients (median PFS 10.8 months vs. 5.4 months
R: 0:30, p < 0.001, in the NEJ002 study, and median PFS
.2 vs. 6.3 HR: 0.489, p  < 0.0001 in WJTOG 3405), which
etermined the premature end of the trial, during the interim
nalysis.
In all these studies, the OS was similar in both arms, prob-
bly because of the high cross-over rate, so that almost all
he patients who progressed after a first-line chemotherapy
eceived a TKI as second-line treatment. A recent meta-
nalysis [69] confirms the results of studies comparing
hemotherapy and gefitinib in first-line treatment showing
 higher RR (72% vs. 38% OR: 4.04) and a statistically sig-
ificant increase in PFS (HR: 0.45) in patients treated with
efitinib selected for EGFR gene activating mutations. On the
asis of this evidence in July 2009 EMA approved gefitinib
or the treatment of locally advanced or metastatic NSCLC
n all treatment lines limited to patients bearing EGFR gene
ctivating mutations. To date gefitinib is considered the best
rst-line option for this molecularly selected subgroup of
atients.
Erlotinib was also compared to chemotherapy in first-line
reatment of NSCLC patients. Two phase III randomized tri-
ls were conducted on a selected population for the presence
f EGFR gene activating mutations: the OPTIMAL study
70] enrolled 154 patients in China, comparing erlotinib vs.
arboplatin–gemcitabine combination, while in the EURTAC
tudy [71] 174 Caucasian enrolled patients were random-
zed to erlotinib vs. platinum-based regimens. In both studies
he primary endpoint has been reached with a median PFS
3.1 months in arm with erlotinib vs. 4.6 months HR: 0.16,
 < 0.0001 (OPTIMAL study), and a median PFS 9.7 vs.
.2 months HR: 0.37, p < 0.0001 (EURTAC study). There-
ore erlotinib has also proven effective in first-line treatment
f NSCLC patients with EGFR mutation. Moreover, it is
he only EGFR TKI, which has been directly tested against
hemotherapy in Caucasian patients.
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A recent meta-analysis [69] included 13 randomized tri-
ls which compared TKIs and chemotherapy in first and
econd-line treatment of 10433 patients selected for the pres-
nce of EGFR gene activating mutations, showing a clear
uperiority of TKIs both in terms of ORR (67,6% vs. 32,8%
R: 2.06) and PFS (HR: 0.30), while no difference was
bserved regarding OS. These results are likely to be influ-
nced by crossover treatments that formally abrogate any
urvival gain. Moreover, the increased benefit is statistically
aintained both in untreated and in treated patients, while
rlotinib appear to have a greater effect on RR and progression
elay than gefitinib.
Some phase II trials have compared erlotinib vs.
hemotherapy in patients with unknown EGFR mutation sta-
us, with conflicting results. A phase II trial [72] compared
rlotinib vs. carboplatin–paclitaxel in the first line treatment
n NSCLC patients with performance status (PS) 2, with rel-
vant results for chemotherapy arm (RR 2% vs. 12% PFS1.9
s. 3.5 months, HR: 1.45, p: 0.6). However these results may
e influenced by patient PS, which is known to influence the
ffectiveness of TKI, as observed in another phase II study
73], in which >75 year-old or PS2 patients were treated
ith erlotinib as first-line treatment, with very disappoint-
ng results (ORR: 21%, median PFS: 1.5 months; median
S: 3.2 months).
Another study on elder people (>0 years, PS0/1) [74],
omparing erlotinib vs. carboplatin–vinorelbine, showed
reater efficacy of chemotherapy (PFS: 4.6 vs. 2.4 months,
: 0.000.5, RR: 28.3% vs. 7.8%, p: 0.000.1). On the other
and, the results of a recent phase II study [75], which
ompared erlotinib versus single-agent chemotherapy with
ral vinorelbine in elderly patients (> 70 years), showed a
tatistically significant advantage in favor of erlotinib (RR:
2.8% vs. 8.9%, PFS: 4:57 vs. 2:53 months, p: 0.02), with
n increase in median PFS that was greater in patients with
GFR activating mutations gene in treatment erlotinib (n: 9,
edian 8.4 months), followed by the same mutated patients
reated with vinorelbine (n: 15, median 3.97 months), and
hen in descending order by patients without mutation treated
ith vinorelbine and erlotinib (median 3.83 and 1.47 months
espectively). These data suggest a possible prognostic value
f EGFR, in additional to the already known predictive value.
urthermore, it raises the possibility of treating with biologic
rugs selected subset of patients (elderly PS 0–1, ineligible
or double platinum) regardless of the mutational status of
GFR, saving them from all the toxic effects of chemother-
py, and even getting a higher efficacy, is promising (Table 3).
.1.3. Use  as  maintenance  treatment
Two recent phase III trials evaluated the use of TKI
n maintaining strategy with good results. In particular,
ATURN study [76] evaluated the erlotinib efficacy in main-enance after 4 cycles of platinum-based chemotherapy, in
 population of unselected patients, showing a statistically
ignificant benefit in terms of PFS (median PFS: 12 vs.
1 weeks, HR: 0.71, p < 0.0001) and OS (median OS: 12
308 G. Bronte et al. / Critical Reviews in Oncolo
Ta
bl
e 
3
R
an
do
m
iz
ed
 
ph
as
e 
II
I t
ria
ls 
o
f c
o
m
pa
ris
on
 
o
f T
K
I v
s 
ch
em
ot
he
ra
py
 
in
 
fir
st-
lin
e 
tr
ea
tm
en
t o
f p
at
ie
nt
s w
ith
 
ad
va
n
ce
d 
N
SC
LC
.
Cl
in
ic
al
 
tr
ia
ls 
IP
A
SS
 
[4
5]
 
FI
R
ST
-
SI
G
NA
L
[4
7]
N
EJ
00
2 
[4
8]
 
W
JT
O
G
 
34
05
[4
9]
 
O
PT
IM
A
L 
[5
1]
 
EU
RT
A
C 
[5
2]
Tr
ea
tm
en
t 
G
efi
tin
ib
 
v
s.
ca
rb
op
la
tin
o-
pa
cl
ita
xe
l
G
efi
tin
ib
 
v
s.
ci
sp
la
tin
o–
ge
m
ci
ta
bi
na
G
efi
tin
ib
 
v
s.
ca
rb
op
la
tin
o–
pa
cl
ita
xe
l
G
efi
tin
ib
 
v
s.
ci
sp
la
tin
o–
do
ce
ta
xe
l
Er
lo
tin
ib
 
v
s.
ca
rb
op
la
tin
o–
ge
m
ci
ta
bi
na
Er
lo
tin
ib
 
v
s.
pl
at
in
um
 
do
ub
le
t
M
ed
ia
n  
PF
S
O
ve
ra
ll  
po
pu
la
tio
n 
5.
7 
v
s.
 
5.
8 
m
o
n
th
s
H
R
: 0
.7
4
6.
1  
v
s.
 
6.
6 
m
o
n
th
s
H
R
: 0
.8
13
EG
FR
-m
ut
at
io
n 
po
si
tiv
e 
H
R
: 0
.4
8
p 
<
 
0.
00
01
8.
7  
v
s.
 
6.
7 
m
o
n
th
s
H
R
: 0
.5
44
10
.8
vs
5.
4  
m
o
n
th
s
H
R
: 0
.3
6
9.
2  
v
s.
 
6.
3 
m
o
n
th
s
H
R
: 0
.4
89
13
.1
 
v
s.
 
4.
6 
m
o
n
th
s
H
R
: 0
.1
6
9.
7  
v
s.
 
5.
2 
m
o
n
th
s
H
R
: 0
.3
7
EG
FR
 
m
u
ta
tio
n 
n
eg
at
iv
e 
H
R
: 1
.3
8 
2.
1 
v
s.
 
6.
4 
m
o
n
th
s
H
R
: 1
.4
19
M
ed
ia
n 
O
S
O
ve
ra
ll  
po
pu
la
tio
n 
18
.6
vs
17
.3
 
m
o
n
th
s
H
R
:  0
.9
0
21
.3
vs
23
.3
 
m
o
n
th
s
H
R
:0
.9
32
EG
FR
 
m
u
ta
tio
n 
po
si
tiv
e 
21
.6
 
v
s.
 
21
.9
 
m
o
n
th
s
H
R
:  1
.0
0
30
.6
 
v
s.
 
26
.5
 
m
o
n
th
s
H
R
:  1
.0
43
30
.5
 
v
s.
 
23
.6
H
R
:  0
.8
87
N
ot
 
av
ai
la
bl
e 
N
ot
 
av
ai
la
bl
e 
N
ot
 
av
ai
la
bl
e
EG
FR
 
m
u
ta
tio
n 
n
eg
at
iv
e 
11
.2
 
v
s.
 
12
.7
 
m
o
n
th
s
H
R
: 1
.3
8
H
R
:  1
.0
0
v
p
w
a
c
s
i
o
t
l
p
i
a
w
c
n
f
e
G
u
o
o
s
0
g
e
l
t
f
4
b
[
e
c
c
T
b
t
o
P
P
E
m
R
p
a
b
s
l
c
t
a
egy/Hematology 89 (2014) 300–313
s. 11 months, HR: 0.81). This advantage was higher in
atients who had SD at the end of chemotherapy, compared
ith those who had a RP. The ATLAS study [77] evalu-
ted the addition of bevacizumab to erlotinib after 1st line
hemotherapy until progression, highlighting a statistically
ignificant increase in PFS (HR: 0.72) and a small benefit
n OS. However the trials for second early line therapy are
ften based on clinical criteria, such as patients with large
umors, symptomatic, PS 0–1, no severe toxicities to first-
ine treatment [78]. Moreover a meta-analysis [79] and a
ooled analysis [80] showed that erlotinib produced signif-
cant clinical benefits (improvements in PFS and OS) with
cceptable toxicity as a maintenance strategy in patients
ith unresectable NSCLC who had not progressed after four
ycles of first-line chemotherapy, even if further studies are
eeded to identify patients that may obtain greater benefits
rom maintenance with erlotinib, and to compare its use as
arly second line to standard second line therapy treatment.
efitinib was also effective on maintaining strategy in an
nselected population of patients who had completed 4 cycles
f platinum-based chemotherapy, regardless of the response
btained in the first-line treatment [81], with a statistically
ignificant benefit in terms of PFS (4.8 months vs. 2.16, HR:
.42, p  < 0.0001) (Table 4). Finally, data suggest that both
efitinib and erlotinib produces a significant survival ben-
fit and maintenance strategy with EGFR TKIs after first
ine chemotherapy is a good treatment strategy in unselec-
ed patients with advanced NSCLC, and an excellent option
or patients with EGFR mutation [82].
.2.  Directly  comparing  studies
There are few studies performing a direct comparison
etween gefitinib and erlotinib. A randomized Phase II trial
83] compared the second-line treatment with gefitinib and
rlotinib, in a population of patients selected on the basis of
linical favorable features (women, non-smokers, adenocar-
inoma) or the presence of EGFR activating gene mutations.
his trial didn’t show statistically significant differences
etween these two drugs regardless EGFR mutational sta-
us. However, the subgroup analysis showed higher activity
f both drugs in patients with EGFR-mutated (ORR: 76.5%;
FS: 11.9 months) than patients with EGFR-WT (ORR: 25%,
FS: 2.8 months, p: 0.001, p: 0.08). In patients with unknown
GFR status, the gefitinib arm achieved a 37% RR and a 4.3
onths median PFS while patients in the erlotinib arm had
R of 55% and PFS of 3.1 months. The small number of
atients greatly reduces the statistical power of this study
nd doesn’t allow the identification of significant differences
etween the two drugs. Similar results emerge from another
tudy [84] that compared the efficacy of both drugs as third-
ine treatment in a population of unselected patients either
linically or on the basis of biomolecular factors, concluding
hat there are no statistically significant differences, although
 slight trend was observed in terms of survival in favor of
rlotinib in patients treated for more than 6 months. The same
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Table 4
Randomized phase III trials on TKI maintenance therapy in patients with advanced NSCLC after first line treatment.
Clinical trials SATURN [57] ATLAS [58] INFORM [60]
Treatment Erlotinib vs. placebo Bevacizumab + erlotinib vs.
bevacizumab + placebo
Gefitinib vs. placebo
First-line treatment Platinum-based
chemotherapy × 4 cycles
Platinum-based
chemotherapy × 4
cycles + bevacizumab
Platinum-based
chemotherapy × 4 cycles
Median PFS 12.3 vs. 11.1 weeks HR: 0.71 4.8 vs. 3.7 months HR: 0.72 4.8 vs. 2.6 months HR: 0.42
Median OS 12 vs. 11 months HR: 0.81 15.9 vs 13.9 months HR: 0.90 18.7 vs 16.9 months HR: 0.84
Table 5
Clinical trials on direct comparison between gefitinib and erlotinib in patients with advanced NSCLC.
Clinical trials Kim ST et al. [61] Kim ST et al. [63] Wu WS et al. [64] Wu JY et al. [65]
Treatment Gefitinib vs. erlotinib
(second-line
treatment)
Gefitinib vs. erlotinib
(pre-treated patients)
Gefitinib vs. erlotinib
(all lines of treatment)
Gefitinib vs. erlotinib
(all lines of treatment)
ORR Overall population 47.9% vs. 39.6% p:
0.269
38% vs. 32.2% p:
0.273
41.9% vs. 42% p: 1.0 46.4% vs. 35.5% p:
0.004
EGFR-mutation positive 51% vs. 57.7% 61.9% vs. 75.4% p:
0.069
EGFR-mutation negative 13.3% vs. 25% 12.8% vs. 13.9% p:
0.84
Median PFS Overall population 4.9 vs. 3.1 months p:
0.336
4.7 vs. 2.7 months p:
0.06
7.6 vs. 7.9 months p:
0.47
5 vs. 2.9 months p:
0.102
EGFR-mutation positive 10.5 vs. 10.3 months
p: 0.32
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4EGFR-mutation negative 
esults of equal efficacy/toxicity in second/third-line treat-
ent are confirmed by another study [85], conducted on 342
atients not selected on the basis of clinical or molecular fac-
ors. Conversely, a retrospective study [86] that compared the
fficacy of gefitinib and erlotinib in patients with lung adeno-
arcinoma and known EGFR mutational status demonstrated
 statistically significant difference between the two treat-
ent arms in favor of erlotinib in EGFR-WT patients (RR:
5% vs 4%, p: 0064; PFS: 4.5 vs. 2.3 months, p: 0.03), while
o differences were observed in patients with EGFR gene
ctivating mutations. However, no differences were found in
erms of OS.
Finally, a previous retrospective study [87] compared
efitinib and erlotinib treatment in a population of 716
atients with advanced NSCLC in all lines of treatment,
howing no statistically significant differences between these
wo drugs in the different lines, regardless of EGFR muta-
ional status. Additional informations about the current use
f these two different drugs in clinical practice, showed that
rlotinib would be used much more frequently than gefitinib
n the treatment of male patients, smokers, not adenocar-
inoma histology (p  < 0.001); both drugs are used more in
st line rather than in 2nd or 3rd line, but gefitinib is much
ore used than erlotinib in this indication (63% vs. 38%, < 0.001). This is certainly due to the fact that erlotinib has
ot been indicated in first-line treatment of NSCLC patients,
lthough all studies compared with chemotherapy have made
d
e2.3 vs. 4.5 months p:
0.03
 clear superiority of erlotinib in patients with activating
utations of the EGFR gene (Table 5).
This trend in the use of these two TKIs could be explained
y the two major comparing studies between TKIs and
lacebo in 2nd-line treatment (ISEL and BR21), which
emonstrated an exclusive benefit of erlotinib in unselected
opulation, and no benefit of gefitinib. However, in contrast to
his finding, there are evidences from 4 studies that compared
he efficacy of gefitinib versus docetaxel in the second-line
or unselected population, as well as the data of the stud-
es that have directly compared erlotinib and gefitinib in
nd–3rd-line, suggesting the absolute equivalence of the two
reatments. In this regard it may be appropriate to review and
e-modulate the directions to the rigid use of the two drugs
n different lines of treatment with the aim of being able
o guarantee to the patient the highest number of treatment
ptions.
Finally, we are eager to know the results of the only Asian
rial currently underway evaluating the direct comparison
etween gefitinib and erlotinib in the treatment of first-line
reatment with NSCLC patients.
.3.  Possibility  of  sequential  administration  of  the  two
rugs
Several studies (retrospective, prospective, case reports)
valuated erlotinib efficacy in patients who had a PD after
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rst-line treatment with gefitinib, showing controversial
esults. Two clinical trials [88,89], in patients selected accord-
ng to specific clinical characteristics (women, non-smokers,
denocarcinoma) reported very low response and survival
ates (RR: 25%, median PFS: 1.5 months). Conversely,
nother study [90], which assessed erlotinib in patients with
he same clinical characteristics, reported significantly higher
esponse rate (RR: 57%), if we consider those patients who
ad a disease control during treatment with gefitinib. Similar
ata were reported in two other studies (DCR 55% and 50%)
91,92]. Studies on patients selected for EGFR mutation
tatus showed higher RR (50%) and DCR (75%) in EGFR-
T patients, who obtained a previous response to gefitinib
92], and no statistically significant benefit in patients who
eveloped resistance to gefitinib [93]. A pooled analysis sum-
arizes the data emerging from individual studies evaluating
equential treatment with erlotinib after failure of gefitinib
r erlotinib [94]. It concludes that a statistically significant
enefit could be achieved in patients selected on the basis
f specific clinical features, who experienced a long-term
isease control during treatment with gefitinib, intended as a
edian PFS of at least 6 months. However the authors suggest
hat the EGFR mutational status couldn’t be considered a pre-
ictor of response for erlotinib after gefitinib failure. A careful
nalysis of response and survival data reported in these stud-
es show a slight trend of effectiveness in favor of patients
ith EGFR-WT. From this observation we could argue that
he biomolecular mechanisms of acquired resistance to gefiti-
ib are common to both these TKIs. In particular, the T790M
GFR mutation and MET amplifications are the most fre-
uent causes of acquired resistance to both these EGFR TKIs.
Besides the higher equivalent erlotinib dose (the dose
dministered coincides with MTD, while the dose of gefit-
nib is equal to 1/3 MTD) and the lower IC50 compared to
efitinib are possible explanations for the theory of different
ensitivity of tumor cells to the two drugs which is observed
n patients with EGFR WT. Another hypothesis to explain
his phenomenon regards the initial presence of both sensi-
ive and resistant clones to TKI. The resistant clones could
ncrease during TKI treatment inducing acquired drug resis-
ance. The amount of resistant clones could be reduced during
ubsequent chemotherapy, thus yielding new sensitivity to
KIs. This theory might also explain the results emerging
rom studies which evaluated the re-administration of gefiti-
ib after failure of the same on the front lines, reporting DCR
f 27% and a median PFS 13.8 months [95]. However, we
ould hypothesize that the clones resistant to gefitinib might
ot be resistant to erlotinib, or be incompletely resistant,
ecause of the presence of unknown mutations and different
rofiles of resistance/sensitivity to the two drugs.
.4.  ToxicityThe analysis of data from individual studies about toxic
ffects of TKIs show a good tolerability profile of both
rugs, with an incidence of adverse events significantly lower
t
s
w
mgy/Hematology 89 (2014) 300–313
ith respect to chemotherapy (61–13% for chemotherapy vs.
efitinib p  < 0.001; dose reduction of 35% vs. 16% for gefit-
nib; in the IPASS study, and 65% vs. 17% for erlotinib;
ose reduction of 53% vs. 6% for erlotinib in the OPTI-
AL). The treatment with these drugs is associated with
 significantly lower incidence of myelosuppression, nau-
ea, vomiting, fatigue, neurotoxicity. The most common
oxic effects most frequently encountered in the course of
reatment with TKIs are rash, diarrhea and asymptomatic
ypertransaminasemia generally mild to moderate, while
evere toxicities are uncommon. Although the toxicity pro-
le is almost comparable in both drugs, a phase II study [83]
omparing the efficacy/toxicity of these two drugs in the 2nd-
ine showed a higher incidence of moderate-to-severe rash
n patients treated with erlotinib (43% vs. 10.4%), as well
s a higher incidence of fatigue. Howevere these toxicities
idn’t affect the dose-intensity or quality of life in the two
reatment arms. A recent meta-analysis [96] has analyzed
ver 24 trials, showing a statistically significant association
etween rash and clinical efficacy of treatment with TKIs
OS: HR:0.30, p  < 0.00001; PFS: HR:0.50, p  < 0.00001), so
hat the authors conclude that the rash can be considered
n independent predictor of effectiveness for TKI treatment,
articularly for patients with EGFR unknown mutational sta-
us. However, a careful analysis of the studies reported in
his meta-analysis and other studies in the literature includ-
ng the recent study of Lilembaum et al. [72] highlights a
ifference regarding skin toxicity. In fact, treatment with
rlotinib is associated with a higher incidence of moderate-
o-severe skin-rash, which seems to be associated with a
tatistically significant outcomes (ORR, PFS, OS), not always
emonstrable during treatment with gefitinib, which is rather
ore frequently responsible for mild–minimal skin toxicities.
hese differences, though slight, there certainly appear rele-
ant and worthy of in-depth in subsequent work.
.  Conclusions
In the last years the introduction of the anti-EGFR TKIs
efitinib and erlotinib represented the most important inno-
ation for the treatment of advanced NSCLC. Infact these
rugs are able to target the main pathway involved in lung
ancer development and progression, the EGFR-mediated
ignaling transduction pathway. Furthermore TKIs allow
paring these patients from chemotherapy and subsequent
uality-of-life-impairing toxicities. However in the first-line
reatment only patients bearing EGFR gene activating muta-
ions could achieve more benefit than chemotherapy.
Since gefitinib and erlotinib have different structure and
ubsequently different affinity with their receptor, toxicity
requency, but similar efficacy results, we postulated that
hese drugs could be partially interchangeable in the deci-
ion making for EGFR-mutated advanced NSCLC patients
ho will undergo a cancer treatment. However these two
olecules are not identical, and we carefully evaluated
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vailable information about a comparison between these
rugs, as well as on a possible complementary role in the
verall management of these patients.
The biological, pharmacological and clinical differences
f anti-EGFR TKIs should represent the starting point for fur-
her studies, at different levels. For instance the clinical results
ivergence should be related to molecular differences, which
ight be evaluated using new standardized procedures. This
hould prompt the development and validation of predictive
ests to select the best drug for each patient. The evaluation of
he possible sequential use of gefitinib and erlotinib is another
ey point in the clinical setting, since it would allow widening
he treatment options.
Since the main goal of advanced cancer treatment is
epresented by prolongation of lifetime together with quality-
f-life preservation, we envision that novel biological and
harmacological insights leading to the optimal use of cur-
ently available targeted drugs could achieve better results
han chemotherapy in the future clinical management of
SCLC patients.
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